(C) 2010 Elsevier Masson SAS. All rights reserved.”
“Backgro

(C) 2010 Elsevier Masson SAS. All rights reserved.”
“Background: Prevention of infection associated with uncemented orthopaedic implants could lead to improved implant stability and better patient outcomes. We hypothesized that coating porous metal implants with antibiotic-containing microspheres would prevent infections in grossly contaminated wounds.

Methods: Bioresorbable polymer microspheres containing tobramycin were manufactured and pressed into porous metal cylinders that were then implanted into radial defects in rabbits. Control implants that did not contain antibiotic

microspheres were also implanted into the contralateral limbs. Each implant was then contaminated with Staphylococcus aureus prior to closure of the wound. The animal was euthanized after Protein Tyrosine Kinase inhibitor clinical signs of infection appeared, or at two weeks after surgery.

Periprosthetic tissue was cultured for the presence of S. aureus, and integration of the implant with the surrounding bone was measured.

Results: The antibiotic microspheres successfully prevented infection in 100% of the eleven limbs with treated implants, which represented a significant improvement (p = 0.004) compared with the infection rate of click here 64% (seven of eleven) for the limbs with control implants. Implant integration averaged 38.87% +/- 12.69% in the fifteen uninfected limbs, which was significantly better (p = 0.012) than the average of 19.46% +/- 14.49% in the seven infected limbs.

Conclusions: The antibiotic delivery system successfully prevented infection in 100% of the cases studied, resulting in an increase in implant integration.”
“The

endothelium-derived vasoconstrictor PXD101 concentration molecule endothelin-1 (ET-1) has been suggested to play a role in the pathogenesis of Raynaud’s phenomenon (RP) and systemic sclerosis (SSc). We studied the effect of bosentan on microvascular structure and function in patients with RP secondary to limited cutaneous SSc in a mechanistic pilot study. In this single center, open study, 15 patients with limited cutaneous SSc were treated with bosentan for 16 weeks with a follow-up period of 4 weeks. Changes in microvascular structure and function were studied with assessment of vasodilatory microvascular responses using laser Doppler fluxmetry combined with iontophoresis, capillary permeability using fluorescence videomicroscopy, nailfold capillary microscopy, and serological markers of endothelial activation. No significant changes were seen in vasodilator responses to acetylcholine and sodium nitroprusside following bosentan treatment. No effect was noted on capillary permeability during treatment. The number of nailfold capillaries remained unchanged.

Comments are closed.